Last 48 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -44.14 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 7.87 | 9.31 | 14.43 | 11.31 | 11.80 | 8.88 | 8.60 | 11.73 | 8.65 | 10.32 | 10.98 | 12.61 | 13.17 | 14.24 | 16.80 | 7.10 | 34.38 | 27.62 | 42.43 | — | — |
| — | +4.8% | +67.8% | -3.6% | +36.4% | -14.0% | -21.7% | -6.9% | -34.3% | -27.5% | -34.6% | +77.7% | -61.7% | -48.4% | -60.4% | — | — | — | — | — | — | |
| P/B Ratio | 74.58 | 91.72 | 151.32 | 158.53 | 104.73 | 82.40 | 70.63 | 107.13 | 72.04 | 46.57 | 37.23 | 26.26 | 19.72 | 12.22 | 11.26 | 24.01 | 30.59 | 11.83 | 98.48 | 107.92 | 91.28 |
| — | +11.3% | +114.2% | +48.0% | +45.4% | +76.9% | +89.7% | +308.0% | +265.2% | +281.2% | +230.8% | +9.4% | -35.5% | +3.3% | -88.6% | -77.8% | -66.5% | -59.3% | +177.4% | +390.4% | +241.3% | |
| P/FCF | — | — | — | — | — | 1537.24 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.6% | 93.1% | 93.8% | 92.3% | 93.7% | 93.0% | 91.0% | 91.9% | 91.1% | 91.9% | 90.8% | 91.6% | 89.7% | 88.7% | 90.2% | 92.0% | 90.6% | 88.6% | 88.9% | — | — |
| — | +0.1% | +3.0% | +0.4% | +2.8% | +1.2% | +0.3% | +0.4% | +1.6% | +3.7% | +0.7% | -0.4% | -1.0% | +0.1% | +1.5% | — | — | — | — | — | — | |
| Operating Margin | -26.5% | -4.3% | -22.7% | -33.1% | -15.0% | -27.0% | -24.5% | -46.9% | -61.1% | -59.8% | -89.5% | -89.7% | -137.4% | -107.5% | -139.3% | -6.7% | -245.8% | -251.8% | -444.2% | — | — |
| — | +84.2% | +7.1% | +29.4% | +75.4% | +54.9% | +72.7% | +47.7% | +55.5% | +44.4% | +35.7% | -1231.0% | +44.1% | +57.3% | +68.6% | — | — | — | — | — | — | |
| Net Margin | -28.7% | -5.0% | -23.5% | -33.8% | -14.6% | -27.6% | -32.0% | -48.9% | -63.1% | -61.7% | -91.0% | -91.1% | -137.9% | -107.6% | -143.8% | -11.9% | -251.3% | -266.1% | -469.8% | — | — |
| — | +82.0% | +26.5% | +31.0% | +76.9% | +55.2% | +64.9% | +46.3% | +54.3% | +42.7% | +36.7% | -668.4% | +45.1% | +59.6% | +69.4% | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -252.1% | -13.6% | -74.4% | -90.3% | -35.3% | -64.3% | -76.0% | -107.8% | -99.9% | -66.0% | -64.3% | -40.8% | -42.8% | -22.7% | -34.4% | -10.1% | -45.9% | -52.0% | -277.2% | -261.4% | -116.5% |
| — | +78.8% | +2.0% | +16.2% | +64.7% | +2.5% | -18.2% | -164.2% | -133.3% | -190.9% | -86.9% | -302.6% | +6.6% | +56.3% | +87.6% | +96.1% | +60.6% | +15.0% | -620.1% | -838.3% | -397.3% | |
| ROA | -29.1% | -1.6% | -7.0% | -9.2% | -4.2% | -7.2% | -7.8% | -10.2% | -13.3% | -11.6% | -14.5% | -12.1% | -16.6% | -10.3% | -13.4% | -3.1% | -18.3% | -17.3% | -30.8% | -44.9% | -33.2% |
| — | +77.5% | +10.3% | +9.8% | +68.3% | +38.0% | +46.5% | +15.4% | +20.1% | -13.5% | -8.1% | -287.3% | +9.2% | +40.5% | +56.4% | +93.1% | +45.1% | +35.7% | -47.9% | -171.2% | -122.2% | |
| ROIC | -1906.7% | -81.0% | — | — | -331.6% | — | — | — | — | — | — | — | -496.8% | -143.5% | -247.5% | -58.2% | -326.0% | -105.8% | -361.8% | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | -52.4% | -35.7% | +31.6% | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.73 | 2.07 | 2.63 | 4.03 | 2.73 | 2.96 | 2.97 | 3.97 | 3.38 | 2.07 | 1.86 | 1.32 | 0.98 | 0.69 | 0.66 | 1.32 | 0.86 | 0.60 | 6.20 | 3.42 | 3.18 |
| — | -30.0% | -11.5% | +1.5% | -19.2% | +43.2% | +59.5% | +201.9% | +246.8% | +200.6% | +181.5% | -0.5% | +12.9% | +14.9% | -89.3% | -61.4% | -72.8% | -48.8% | +784.2% | +557.2% | +622.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.55 | 1.42 | 1.43 | 1.39 | 1.55 | 1.57 | 1.57 | 2.03 | 2.11 | 2.44 | 2.48 | 3.20 | 3.63 | 4.46 | 4.52 | 3.02 | 2.54 | 4.19 | 2.44 | 3.54 | 3.75 |
| — | -9.4% | -9.1% | -31.4% | -26.2% | -35.7% | -36.8% | -36.6% | -42.0% | -45.3% | -45.1% | +5.7% | +42.8% | +6.6% | +85.1% | -14.5% | -32.2% | -10.1% | -60.6% | -53.5% | -52.2% | |
| Quick Ratio | 1.48 | 1.34 | 1.34 | 1.32 | 1.48 | 1.50 | 1.51 | 1.96 | 2.04 | 2.37 | 2.40 | 3.09 | 3.52 | 4.38 | 4.44 | 2.95 | 2.50 | 4.15 | 2.20 | 3.54 | 3.75 |
| — | -11.0% | -11.3% | -32.7% | -27.4% | -36.6% | -36.9% | -36.5% | -42.1% | -45.9% | -45.9% | +4.8% | +41.0% | +5.4% | +101.8% | -16.7% | -33.4% | -10.8% | -64.5% | -53.5% | -52.2% | |
| Interest Coverage | -27.02 | -6.43 | -32.24 | -53.47 | -23.00 | -41.17 | -24.44 | -23.44 | -32.86 | -31.66 | -60.08 | -62.18 | -139.99 | -82.06 | -23.83 | -2.82 | -45.30 | -17.59 | -17.36 | -28.51 | -23.83 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AXSM stock.
Axsome Therapeutics, Inc.'s current P/E is -44.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Axsome Therapeutics, Inc.'s current operating margin is -26.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Axsome Therapeutics, Inc.'s business trajectory between earnings reports.